معرفی
Mats Ljungman, PhD, is a Professor of Radiation Oncology at the Medical School and Professor of Environmental Health Sciences at the School of Public Health, University of Michigan. He serves as a Center Member at the Center for Computational Medicine and Bioinformatics, Rogel Cancer Center, and Precision Health Initiative. His research focuses on carcinogenesis, DNA damage responses, and transcription regulation, driven by the Bru-seq technology platform for nascent RNA analysis and the KLIPP CRISPR-based cancer targeting system. He collaborates globally and participates in the ENCODE 4 project.
Qualifications include a postdoctoral fellowship at Stanford University (1994). His lab develops novel techniques like Bru-seq to study transcription start sites, splicing kinetics, and transcription elongation rates, providing insights beyond traditional RNA-based methods. Collaborations span medicinal chemistry for drug mechanism studies and RNA exosome inhibitors as cancer therapies.
Recent work includes CRISPR-based precision targeting of tumor-specific structural variants, mechanistic studies of DNA repair pathways, and investigations into IL-1 signaling in skin diseases. His lab’s KLIPP technology aims to selectively destroy cancer cells without affecting healthy tissue, leveraging unique tumor genomic features.
